Hadassah

Clinical Trial at Hadassah Hospital Yields Positive Results With Noninvasive Test for Liver Cancer

Monday, Oct 24 2011

A clinical trial conducted at the Hadassah University Medical Center has revealed that BreathID, a new noninvasive device for the detection of hepato-cellular carcinoma, a type of liver cancer, achieved diagnostic results similar to CT Scans and MRIs. BreathID was developed by Exalenz Bioscience Ltd., whose Medical Director is Prof. Yaron Ilan, Director of Hadassah's Department of Internal Medicine.

The 36 patients in the trial were first checked by ultrasound; those suspected to have liver cancer underwent a CT Scan or MRI, which revealed that 26 patients had the disease. All the patients were then given breath tests with the BreathID device to determine whether it could achieve similar statistically meaningful results. The device achieved a congruence of 93 percent. Exalenz now plans to begin a larger trial of the device, which will involve 100 patients at five hospitals in Israel, the United States, and Canada.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Jun 19 2019

Happiness in the Intensive Care Unit: A Father Expresses His Anticipatory Joy

“My name is Yoel Fadel. Today is a very special day for me. My youngest son, Benny, is getting married. He will walk to the wedding canopy with his sweetheart, but I cannot attend the wedding.

READ MORE ›
alt_text

Wednesday, Jun 19 2019

Helping with a Full Heart: A Mitzvah Passed on at Hadassah Mount Scopus

They met in the Pediatrics Department at Hadassah Hospital Mount Scopus, two couples whose children suffer from a rare disease.

READ MORE ›
alt_text

Tuesday, Jun 18 2019

Diabetes: An Ongoing Struggle

Prof. Gil Leibowitz, head of the Diabetes Unit at the Hadassah Medical Organization’s Endocrinology and Metabolism Service, remembers himself as a scared, skinny seven-year-old when the doctor told his parents that he had type 1 diabetes.

READ MORE ›
alt_text

Wednesday, Jun 12 2019

Multinational Study Reveals Reduction in Kidney Disease Progression with Diabetes Drug

In a large multinational study that revealed the effectiveness of a medicine called dapagliflozin in reducing cardiovascular death from heart failure among high-risk diabetic patients, the first sub-analysis of renal data has also identified a 47 percent drop in decline of kidney function and renal death.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More